Overview

Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this one year extension (follow-up) study is to gather additional safety data in hypogonadal men treated with oral TU or AndroGel who have completed the 12-month Phase III study CLAR-09007.
Phase:
Phase 3
Details
Lead Sponsor:
Clarus Therapeutics, Inc.
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate